Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells

MINGSHI ZHANG1, JINRUI LIU1, MINGJUN LI1, SHIHUA ZHANG1, YANMEI LU1, YANQIU LIANG2, KAI ZHAO3 and YINGFU LI1

Departments of 1Neurosurgery and 2Radiology, The First Affiliated Hospital of Jiamusi University; 3Graduate School, Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China

Received May 16, 2016; Accepted March 24, 2017

DOI: 10.3892/etm.2018.6336

Abstract. Glioblastoma multiforme (GBM) is a malignant tumor caused by complex pathological mechanisms, and is characterized by a high rate of cancer-related mortality and poor patient prognosis. Overgrowth of cancer cells, which results from the inhibition of cell apoptosis and/or the promotion of cell proliferation, leads to the progression of GBM. Therefore, studies into the regulatory mechanisms of cancer cell growth in GBM are required to identify potential therapeutic targets and improve treatment for GBM. In the present study, the role of insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) signaling in the survival of GBM cells was evaluated. It was observed that IGF1 significantly inhibited the intrinsic and extrinsic pathways of apoptosis (P<0.05), and overexpression of IGF1R significantly promoted the survival of GBM cells (P<0.05). Moreover, both exogenous IGF1 and overexpression of IGF1R promoted the phosphorylation of protein kinase B (AKT), and inhibition of the phosphoinositide 3-kinase (PI3K)/AKT pathway significantly attenuated the inhibitory effects of IGF1/IGF1R on GBM apoptosis (P<0.05). Collectively, these findings indicate that IGF1/IGF1R on GBM promote the survival of GBM cells through activation of the PI3K/AKT pathway. Therefore, inhibition of IGF1/IGF1R may be a viable therapeutic strategy to suppress the progression of GBM.

Introduction

Glioblastoma multiforme (GBM) originates from glial cells and is the most prevalent and critical form of brain cancer (1). GBM cells are characterized by their propensity to invade surrounding brain tissue adjacent to the main tumor mass (2). Although surgical resection combined with radiotherapy and/or chemotherapy is currently used as a standard treatment for GBM, the median survival rate of patients with GBM is <15 months (3,4). Tumor recurrence, as a primary reason for the high mortality rate of GBM patients, is principally caused by residual tumor cells that remain within tissues following various treatments (5). Cellular apoptosis is negatively correlated with cell growth, and the inhibition of cell apoptosis is primarily responsible for cancer cell survival. Therefore, induction of apoptosis is considered to be a potential therapeutic strategy for the eradication or suppression of cancer cell growth and tumor progression (6,7). However, the mechanism responsible for regulating cancer cell survival in GBM remains unknown and warrants investigation.

Results suggest that insulin-like growth factor 1 (IGF1) and its receptor tyrosine kinase [insulin-like growth factor 1 receptor (IGF1R) are key regulators in the development and progression of cancer (8). Previous studies have demonstrated that the IGF1/IGF1R pathway is involved in regulating tumorigenesis, cell growth and metastasis in many cancers, and that some physiological functions, including cell cycle progression, apoptosis and differentiation, are associated with the IGF1/IGF1R pathway (9,10). In colon cancer cells, it has also been documented that activation of IGF1/IGF1R induced by incubation with tumor necrosis factor lead to cellular resistance to apoptosis (11). Furthermore, inhibition of the IGF1/IGF1R pathway may reduce tumorigenesis and attenuate tumor progression through the induction of apoptosis in cancer cells (12). However, the role of IGF1/IGF1R signaling in the survival of GBM cells and the corresponding molecular mechanisms are not well understood.

In the present study, it was observed that exogenous IGF1 or overexpression of IGF1R protected against apoptosis and promoted the survival of GBM cells. Mechanistic assays also indicated that the inhibitory effects of IGF1/IGF1R on GBM apoptosis were mediated by the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway. These results suggest that targeting of IGF1/IGF1R signaling may aid to improve the efficacy of treatments for GBM.

Correspondence to: Dr Yingfu Li, Department of Neurosurgery, The First Affiliated Hospital of Jiamusi University, 348 Dexiang Road, Jiamusi, Heilongjiang 154002, P.R. China
E-mail: yingfulijd@tom.com

Key words: insulin-like growth factor, apoptosis, glioblastoma multiforme, protein kinase B pathway
Materials and methods

Cell culture. The glioblastoma cell line U87 was obtained from the American Type Culture Collection (Manassas, VA, USA). U87 cells were maintained in an incubator at 37°C and 5% CO₂. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) and 10⁵ U/l penicillin-streptomycin (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for three days.

Cell viability assay. U87 cells were seeded into 96-well plates in DMEM with 10% FBS at a density of 5x10⁴ cells/well and incubated at 37°C for 12 h. Cells were then treated at 37°C with 200 µM H₂O₂ (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 2.5, 5, 10 and 20 ng exogenous IGF (PeproTech, Rocky Hill, NJ, USA), 10 µM wortmannin (Beyotime Institute of Biotechnology, Haimen, China) and 2 µg IGFIR plasmid (Addgene, Inc., Cambridge MA, USA) for 48 h (13). U87 cells cultured in 10% FBS DMEM treated with PBS were used as control. Following treatment, cell proliferation was assessed using a Cell Counting Kit 8 (CCK8) Cell Proliferation Assay kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer’s instructions. Briefly, CCK8 reagent (5 µl) was added to each well and incubated at 37°C for 2 h, and the number of viable cells was calculated from absorbance measurements at 450 nm.

Lactate dehydrogenase (LDH) release assay. The release of LDH from U87 cells cultured in 10% FBS DMEM was measured to determine cell viability according to the manufacturer’s protocol of a CytoTox‑One™ Homogenous Membrane Integrity Assay kit (Promega Corporation, Madison, WI, USA). Cells were seeded at a density of 5,000 cells per well. Fluorescence (excitation at 480 nm; emission maximum at 560-590 nm) was assessed using a Spectramax Gemini XS Microplate Spectrofluorometer (Molecular Devices LLC, Sunnyvale, CA, USA). The cytotoxicity of treated U87 cells was calculated as the relative increase in LDH compared with that of untreated control cells.

Caspase-3 activity assay. A total of 5x10⁴ U87 cells were lysed in caspase buffer [10 mM Tris-HCl, 10 mM NaH₂PO₄, 130 mM NaCl, 1% (v/v) Triton X-100], and extracts were clarified by centrifugation at 16,099 x g for 10 min at 4°C, and protein concentrations were determined using a Bradford Protein Assay kit (Beyotime Institute of Biotechnology). A total of 50 µg cell protein was loaded per lane of a 12% SDS PAGE gel for separation by electrophoresis. Separated proteins were then transferred onto nitrocellulose membranes (Whatman, Inc., Florham Park, NJ, USA) and immunoblotted with primary antibodies against IGF1R (ab39675; Abcam, Cambridge, MA, USA; 1:1,000), Fas ligand (sc-6237), B-cell lymphoma 2 (Bcl-2; sc-492), Akt (sc-1618), phosphorylated (p)-Akt (sc-33437) and beta-actin (sc-1616; Santa Cruz Biotechnology, Inc., Dallas, CA, USA; 1:8,000 for beta-actin and 1:500 for the remaining antibodies) at 4°C overnight. The blots were incubated with secondary antibodies of horseradish peroxidase conjugated (HRP) mouse anti-goat IgG (sc-2354) or mouse anti-rabbit IgG-HRP (sc-2357; both Santa Cruz Biotechnology, Inc.; 1:5,000) at room temperature for 1 h, then reacted with an enhanced chemiluminescence substrate (Pierce; Thermo Fisher Scientific, Inc.). Resulting band intensities were recorded on an X-ray film. Quantity One software v4.62 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was utilized to assess the protein bands, and all experiments were repeated three times.

Statistical analysis. Statistical analysis was performed using SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). Data were expressed as the mean ± standard error of the mean of three independent experiments, and a Student's t-test was used to determine the statistical significance of results. Differences were considered to be significant when P<0.05.

Results

IGF1 promotes survival and suppresses apoptosis in GBM cells. To detect the role of IGF1 in the survival of GBM cells, 200 µM H₂O₂ was used to establish a cell apoptotic model. Different concentrations of IGF1 (2.5, 5, 10 and 20 ng) were initially administered to determine the optimal concentration of IGF1 for subsequent experiments in U87 cells. Results of a CCK8 assay indicated that treatment with H₂O₂ significantly decreased the viability of U87 cells compared with controls (P<0.05; Fig. 1A), while IGF1 concentrations of 10 and 20 ng significantly restored cell viability (both P<0.05; Fig. 1A). Similarly, a cell death assay demonstrated that LDH release was markedly enhanced by 200 µM H₂O₂, while 10 and 20 ng IGF1 significantly attenuated the release of LDH induced by H₂O₂ (both P<0.05; Fig. 1B). These results suggest that IGF1 promotes cell growth and inhibits cell death at doses of ≥10 ng, indicating that the optimal dose of IGF1 in regulating the survival of GBM cells is 10 ng.

IGF1 inhibits the extrinsic and intrinsic pathways of apoptosis. To identify the role of IGF1 in apoptosis, it was determined whether the intrinsic and/or extrinsic pathways of apoptosis were affected by IGF1. Key molecules in each pathway were detected in response to IGF1 treatment. Caspase-3, a final executor of cell apoptosis, is activated by various stimuli in the process of cell apoptosis (15). Expression of Fas ligand is specifically increased during the extrinsic pathway of apoptosis, and Bcl-2, as an anti-apoptotic protein localized to the outer mitochondrial membrane, is involved in the intrinsic...
pathway of cell apoptosis (15). The present results demonstrated that caspase-3 was significantly activated in U87 cells following H$_2$O$_2$ treatment (P<0.05 vs. control), and that this effect was significantly attenuated by 10 ng IGF1 (P<0.05; Fig. 2A). Furthermore, H$_2$O$_2$ increased the expression of Fas and decreased the expression of Bcl-2, while treatment with IGF1 reversed these changes (Fig. 2B and C). These results indicate that IGF1 may promote the survival of GBM cells.

Overexpression of IGF1R inhibits apoptosis and promotes survival in GBM cells. Stable overexpression of IGF1R was established in U87 cells by lentiviral infection. As depicted in Fig. 3A, the efficiency of IGF1R overexpression was verified by western blot analysis. A subsequent CCK8 assay indicated that the viability of U87 cells was significantly suppressed by H$_2$O$_2$ treatment (P<0.05 vs. control), and that this effect was significantly attenuated by overexpression of IGF1R (P<0.05; Fig. 3B). Similarly, the elevated rate of cell death induced by H$_2$O$_2$ (P<0.05 vs. control) was significantly reduced by overexpression of IGF1R (P<0.05), as determined by an LDH release assay (Fig. 3C). Furthermore, the increased activity of caspase-3 induced by H$_2$O$_2$ (P<0.05 vs. control) was significantly reduced by overexpression of IGF1R (P<0.05; Fig. 3D). These results suggest that activation of the IGF1/IGF1R pathway suppresses apoptosis and promotes survival in GBM cells.

IGF1/IGF1R inhibits cell apoptosis by activating the PI3K/AKT pathway. The PI3K/AKT pathway is a critical pathway in the regulation of cell apoptosis. Therefore, it was determined whether a regulatory relationship existed between IGF1/IGF1R and the PI3K/AKT pathway in U87 cells. As depicted in Fig. 4A and B, it was observed that both exogenous IGF1 treatment and overexpression of IGF1R induced the phosphorylation of AKT. Furthermore, wortmannin, as an inhibitor of the PI3K/AKT pathway (16), was used to determine the role of PI3K/AKT in the inhibition of cell apoptosis by IGF1/IGF1R. It was observed that the increases in cell viability induced by exogenous IGF1 or IGF1R overexpression were significantly reversed by 10 µM wortmannin (P<0.05; Fig. 4C and D). Furthermore, inhibition of caspase-3 activation by IGF1/IGF1R was significantly attenuated by wortmannin (P<0.05; Fig. 4E and F). Therefore, the inhibitory effects of IGF1/IGF1R on GBM apoptosis may be mediated by PI3K/AKT signaling.

Discussion

It has been established that the progression and development of glioblastoma is primarily due to the overgrowth of cancer cells, determined by the balance between the growth and death of cells (17). Previous results have indicated that a dysfunction in cell apoptosis may be responsible for the initiation of many human diseases, including glioblastoma (18). Inhibition of cell apoptosis is frequently observed in the tissues of glioblastoma patients, and thus the regulation of cell apoptosis is considered to be a potential strategy in preventing the progression...
ZHANG et al.: IGF1/IGF1R PROTECTS AGAINST APOPTOSIS THROUGH PI3K/AKT IN GLIOBLASTOMA

of glioblastoma (19). Therefore, studies into the regulatory mechanisms of apoptosis in GBM cells are required to improve the efficacy of molecular therapy. In the present study, it was observed that IGF1/IGF1R protected against apoptosis and
promoted the survival of GBM cells, and that the regulatory effects of IGF1/IGF1R on apoptosis were potentially mediated by PI3K/AKT signaling.

Previous studies have demonstrated that IGF1R, as a key regulator of mitogenesis and tumorigenicity, participates in regulating cell transformation, cell growth and cell cycle progression (20,21). IGF1 is a specific ligand of IGF1R, and upon binding to IGF1R, activates a cascade of intracellular molecular pathways, which may occur during the development and progression of a number of diseases, including cancer (22). IGF1/IGF1R and downstream targets are important in the regulation of cell transformation (23), invasion (24), tumor metastasis (25) and cell survival (9). Although overexpression of IGF1 and IGF1R has been observed in a subset of cancer tissues from patients with GBM (26), the consequences of IGF1/IGF1R overexpression on the survival of GBM cells and the corresponding molecular mechanisms are not well understood. In the present study, it was observed that IGF1 promoted cell survival and suppressed cell death at doses of ≥10 ng. Furthermore, both exogenous IGF1 and IGF1R overexpression inhibited the intrinsic and extrinsic pathways of apoptosis in GBM cells. These results indicated that activation of IGF1/IGF1R promoted the survival of GBM cells by inhibiting apoptosis.

The PI3K/AKT pathway, as a critical pro-survival signaling pathway, modulates cell growth, proliferation, apoptosis and survival in a number of cell types (27). It has been documented that increased phosphorylation of AKT at Ser/Thr sites was associated with the inhibition of cell apoptosis (28). Moreover, aberrant activation of the PI3K/AKT pathway has been observed in a number of tumor tissues, including GBM, and inhibitors of the PI3K/AKT pathway have been investigated as a potential anticancer therapy (29). However, the regulatory mechanisms underlying the PI3K/AKT pathway in the progression of GBM remain unknown. In the present study, it was demonstrated that IGF1/IGF1R promoted the activation of PI3K/AKT signaling in GBM cells. Specifically, the results indicated that both exogenous IGF1 and IGF1R overexpression...
led to increased phosphorylation of AKT. Furthermore, the inhibitory effects of IGF1/IGF1R on the apoptosis of GBM cells were attenuated by inhibition of the PI3K/AKT pathway. These results suggested that IGF1/IGF1R promotes the growth and survival of GBM cells, at least in part through the PI3K/AKT pathway.

In conclusion, the present study indicated that IGF1/IGF1R promoted cell survival and inhibited cell apoptosis through activation of the PI3K/AKT pathway. These results have identified a potential regulatory mechanism underlying the growth of cancer cells in GBM, and targeting of IGF1/IGF1R may aid to improve the efficacy of treatment for GBM.

References